United Therapeutics Corporation

As of June 30, 2026, United Therapeutics Corporation carries a market capitalization of 20.22B, placing it among publicly traded companies globally. Its enterprise value stands at 17.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

United Therapeutics Corporation's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, United Therapeutics Corporation has 42.68M shares outstanding.

As of June 30, 2026, United Therapeutics Corporation trades at a trailing price-to-earnings ratio of 17.88. The price-to-sales ratio is 7.43, and the price-to-book ratio stands at 3.61.

As of June 30, 2026, United Therapeutics Corporation trades at an EV/EBITDA multiple of 13.69 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. United Therapeutics Corporation trades at an EV/FCF ratio of 18.53, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 17.89B versus a market cap of 20.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, United Therapeutics Corporation maintains a current ratio of 5.73, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, United Therapeutics Corporation posted a return on equity (ROE) of 19.32, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 17.21 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.33, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 19.46, useful for judging operating efficiency across full business cycles. The company generates approximately 2.01M in revenue per employee across its workforce of 1,376.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.41 indicates how many times United Therapeutics Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, United Therapeutics Corporation recorded 229.42M in income tax expense. That works out to an effective tax rate of 16.66, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.38B, leaving 1.15B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, United Therapeutics Corporation's stock has gained approximately 43.52% over the past 52 weeks. The 50-day moving average sits at 452.48, while the 200-day moving average is 456.63.

Over the twelve months ended June 30, 2026, United Therapeutics Corporation generated 2.76B in revenue and converted that into 1.15B in net income, yielding earnings per share of 24.47. EBITDA reached 1.31B, while operating income came in at 1.23B.

These figures are as of June 30, 2026. Total book value stands at 5.60B, with working capital of 2.52B providing operational flexibility.

United Therapeutics Corporation produced 1.48B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -518.35M in capital expenditures, free cash flow totaled 956.70M - equivalent to 22.09 per share.

Over the twelve months ended June 30, 2026, United Therapeutics Corporation posted a gross margin of 86.14, reflecting its pricing power and cost economics. The operating margin of 44.49 and net profit margin of 41.56 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.30, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to United Therapeutics Corporation shareholders.

United Therapeutics Corporation's most recent stock split took place on September 23, 2009 with a 1:2 split ratio.

As of June 30, 2026, United Therapeutics Corporation has an Altman Z-Score of 20.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.